|
Title
|
|
|
|
An overview of binimetinib for the treatment of melanoma
|
|
|
Author
|
|
|
|
|
|
|
Abstract
|
|
|
|
| Introduction: Approximately 50% of patients with metastatic melanoma have mutations in BRAF. Based on the results of prior phase III trials, the combination of a BRAF inhibitor (BRAFi) and a MEK inhibitor (MEKi) is the standard of care in patients with BRAF-mutant metastatic melanoma. Areas covered: The author summarizes the available data on binimetinib, a reversible inhibitor of the kinase activity of MEK1 and MEK2, in BRAF- and NRAS-mutated melanoma. Expert opinion: With the advent of binimetinib and encorafenib, clinicians can choose between three BRAFi/MEKi combinations. Indirect comparison and a network meta-analysis suggest that binimetinib plus encorafenib is at least as active as the other two BRAFi/MEKi combinations and that safety is similar. The choice should be guided by the slightly different toxicity profile, local availability, and product experience. The optimal sequence of immunotherapy and BRAFi/MEKi in patients with BRAF-mutated tumors is unclear. As the response to BRAF/MEK inhibition is usually prompt and response to immunotherapy can be delayed, clinicians often choose a BRAFi/MEKi combination as first-line therapy in patients with rapidly evolving and threatening disease. Single-agent binimetinib almost doubled median progression-free survival when compared to dacarbazine in patients with NRAS-mutated melanoma. |
|
|
|
Language
|
|
|
|
English
|
|
|
Source (journal)
|
|
|
|
Expert opinion on pharmacotherapy. - London
|
|
|
Publication
|
|
|
|
Abingdon
:
Taylor & francis ltd
,
2020
|
|
|
ISSN
|
|
|
|
1465-6566
|
|
|
DOI
|
|
|
|
10.1080/14656566.2020.1729122
|
|
|
Volume/pages
|
|
|
|
p. 1-8
|
|
|
ISI
|
|
|
|
000516915800001
|
|
|
Pubmed ID
|
|
|
|
32100585
|
|
|
Full text (Publisher's DOI)
|
|
|
|
|
|
|
Full text (publisher's version - intranet only)
|
|
|
|
|
|